search
Back to results

Bioactive Glass or Allogenic Bone in Pediatric Bone Cysts

Primary Purpose

Bone Cysts

Status
Unknown status
Phase
Not Applicable
Locations
Finland
Study Type
Interventional
Intervention
Bioactive glass
Sponsored by
Turku University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Bone Cysts

Eligibility Criteria

1 Year - 18 Years (Child, Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Suspected aneurysmatic bone cyst in all areas, not spinal.
  2. Other large simple bone cyst in load bearing areas
  3. Simple or aneurysmal bone cyst and a pathological fracture in non load-bearing areas

Exclusion Criteria:

  1. Malignancy
  2. Bone marrow disease
  3. Other than aneurysmatic or simple bone cyst
  4. A secondary aneurysmal bone cyst (ABC associated with another underlying lesion)

Sites / Locations

  • Helsinki University HospitalRecruiting
  • Kuopio University HospitalRecruiting
  • Oulu University HospitalRecruiting
  • Tampere University HospitalRecruiting
  • Turku University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Bioactive glass

Allogenic bone

Arm Description

20 bone cysts (in 20 patients) are filled with bioactive glass

20 bone cysts (in 20 patients) are filled with allogenic bone

Outcomes

Primary Outcome Measures

Recurrence rate
Cyst's recurrence
Recurrence size
The size of cyst recurrence
Operation time
Time from the cut to the closure
Blood loss
Operation's blood loss
Complication
Complications at the operation
Complication
Complications during follow-up
Hospital Stay
Number of days spent at the hospital
Cyst-healing grade (Enneking's grading system)
Enneking's grading system (scale 1-3, 1=latent, 2=active, 3=aggressive)
Function (Musculoskeletal society tumor score)
Musculoskeletal society tumor score (scale 0-5, 5=best outcome, 0=worst outcome)
Fracture after operation
Fracture after operation at the filled area in radiograph (yes / no)

Secondary Outcome Measures

Full Information

First Posted
December 11, 2020
Last Updated
February 1, 2021
Sponsor
Turku University Hospital
Collaborators
Bonalive Biomaterials Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT04737590
Brief Title
Bioactive Glass or Allogenic Bone in Pediatric Bone Cysts
Official Title
A Randomized Clinical Trial Comparing Curettage With Allogenic Bone Grafting and Curettage With Bioactive Glass Filling in Children With Bone Cysts CYSTS
Study Type
Interventional

2. Study Status

Record Verification Date
February 2021
Overall Recruitment Status
Unknown status
Study Start Date
September 5, 2012 (Actual)
Primary Completion Date
December 31, 2022 (Anticipated)
Study Completion Date
December 31, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Turku University Hospital
Collaborators
Bonalive Biomaterials Ltd

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The Finnish Paediatric Orthopedic Study Group will perform a prospective, randomized, multicenter, clinical trial comparing two bone substitutes (allograft and bioactive glass, BonAlive®) in treating bone cysts in children (18 years or younger). The trial is carried out in five University Hospitals (Turku, Helsinki, Tampere, Oulu, Kuopio) in Finland.
Detailed Description
Twenty patients will be randomized into each group. In all University Hospitals the treatment protocol will be same. Randomization will be performed using a sealed envelope technique. Before surgery all patients will be examined clinically. After conventional radiographs all patients will be examined with magnetic resonance imaging showing cyst's size, anatomy, location and adjacent structures. If the aneurysmal bone cyst is large or in difficult location, embolization by the radiologist can be used preoperatively. Surgical technique: Surgery will be done by experienced paediatric orthopaedic surgeons. Normal orthopaedic exposures will be used. The cyst is opened so that square window is done to the cortex. A sample to the pathologist is collected, also intraoperative frozen section is used to confirm the diagnosis. A mechanical curettage with use of a curette and a high speed burr is used to inspect the whole cavity. The tumour is resected as thoroughly as possible. After curettage 5% phenol is inserted to the cavity and it is neutralized with saline. Cyst volume is evaluated using saline (ml). Then the cyst is filled with morsellized femoral head allograft or bioactive glass (BG-S53P4) according to randomization. The biggest granule size 2-3,15mm is used for femur, tibia, pelvis and humerus. If the cyst volume is below 10ml in these places then smaller granule size (1-2mm) is chosen. If the cyst is in hand region then the granule size is 0,5-0,8mm. At the end of the operation the window's roof is inserted back. All the time X-ray is used to ensure that the whole cyst is treated properly. Osteosynthesis will be performed whenever it is necessary to prevent a pathological fracture. After surgery the diagnosis will be confirmed histopathologically. All patients will receive standard anesthesia. Postoperatively an X-ray will be taken. Radiographic controls after surgery will be held at 1 Mo, 3 Mo, 6Mo, 12Mo and 24Mo. Three months control and two years control will be accompanied with MRI. If the cyst is found after a pathologic fracture, the fracture is healed first with the cast +/- traction and MRI will be taken before surgery.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bone Cysts

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Bioactive glass
Arm Type
Active Comparator
Arm Description
20 bone cysts (in 20 patients) are filled with bioactive glass
Arm Title
Allogenic bone
Arm Type
Active Comparator
Arm Description
20 bone cysts (in 20 patients) are filled with allogenic bone
Intervention Type
Device
Intervention Name(s)
Bioactive glass
Intervention Description
Comparison of bioactive glass to allogenic bone in pediatric bone cysts
Primary Outcome Measure Information:
Title
Recurrence rate
Description
Cyst's recurrence
Time Frame
through study completion, average 2 years
Title
Recurrence size
Description
The size of cyst recurrence
Time Frame
through study completion, average 2 years
Title
Operation time
Description
Time from the cut to the closure
Time Frame
during the surgery
Title
Blood loss
Description
Operation's blood loss
Time Frame
during the surgery
Title
Complication
Description
Complications at the operation
Time Frame
during the surgery
Title
Complication
Description
Complications during follow-up
Time Frame
through study completion, average 2 years
Title
Hospital Stay
Description
Number of days spent at the hospital
Time Frame
immediately after the surgery
Title
Cyst-healing grade (Enneking's grading system)
Description
Enneking's grading system (scale 1-3, 1=latent, 2=active, 3=aggressive)
Time Frame
through study completion, average 2 years
Title
Function (Musculoskeletal society tumor score)
Description
Musculoskeletal society tumor score (scale 0-5, 5=best outcome, 0=worst outcome)
Time Frame
through study completion, average 2 years
Title
Fracture after operation
Description
Fracture after operation at the filled area in radiograph (yes / no)
Time Frame
through study completion, average 2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Suspected aneurysmatic bone cyst in all areas, not spinal. Other large simple bone cyst in load bearing areas Simple or aneurysmal bone cyst and a pathological fracture in non load-bearing areas Exclusion Criteria: Malignancy Bone marrow disease Other than aneurysmatic or simple bone cyst A secondary aneurysmal bone cyst (ABC associated with another underlying lesion)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Johanna Syvänen, PhD
Phone
+358 2 313 0000
Email
johanna.syvanen@tyks.fi
First Name & Middle Initial & Last Name or Official Title & Degree
Ilkka Helenius, Prof
Email
ilkka.helenius@tyks.fi
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ilkka Helenius, Prof
Organizational Affiliation
University of Helsinki
Official's Role
Study Director
Facility Information:
Facility Name
Helsinki University Hospital
City
Helsinki
Country
Finland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yrjänä Nietosvaara, PhD
Email
yrjana.nietosvaara@hus.fi
Facility Name
Kuopio University Hospital
City
Kuopio
Country
Finland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jenni Jalkanen, Phd
Email
jenni.jalkanen@kys.fi
Facility Name
Oulu University Hospital
City
Oulu
Country
Finland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Juha-Jaakko Sinikumpu, Prof
Email
juha-jaakko.sinikumpu@ppshp.fi
Facility Name
Tampere University Hospital
City
Tampere
Country
Finland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anne Salonen, PhD
Email
anne.salonen@pshp.fi
Facility Name
Turku University Hospital
City
Turku
Country
Finland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Johanna Syvänen, PhD
Phone
+358 2 313 0000
Email
johanna.syvanen@tyks.fi

12. IPD Sharing Statement

Learn more about this trial

Bioactive Glass or Allogenic Bone in Pediatric Bone Cysts

We'll reach out to this number within 24 hrs